Biglycan (BGN) was found to be associated with tumor progression in gastric cancer (Hu et al., 2014), pancreatic adenocarcinoma (Aprile et al., 2013), endometrial cancer (Liu et al., 2014), and prostate cancer (Jacobsen et al., 2017). Here, BGN is linked to prostate cancer.